• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by PTC Therapeutics Inc.

    4/30/25 4:31:07 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTCT alert in real time by email
    DEFA14A 1 tmb-20250428xdefa14a.htm DEFA14A

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.        )

    Filed by the Registrant ☑

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ​

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☑

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    ​

    ​

    PTC Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ​

      þ     No fee required.

    ☐  Fee paid previously with preliminary materials.

    ☐  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-111.

    ​

    ​


    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V70297-P31069 PTC THERAPEUTICS, INC. 500 WARREN CORPORATE CENTER DRIVE WARREN, NJ 07059 PTC THERAPEUTICS, INC. 2025 Annual Meeting June 17, 2025 9:00 AM ET Virtual Meeting Site: www.virtualshareholdermeeting.com/PTCT2025 Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 17, 2025 You invested in PTC THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the 2025 Annual Meeting. Vote Virtually at the 2025 Annual Meeting* Vote on June 17, 2025 9:00 AM ET Visit www.virtualshareholdermeeting.com/PTCT2025 *Please check the proxy and www.virtualshareholdermeeting.com/PTCT2025 for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and 2024 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Advance of the 2025 Annual Meeting Vote by June 16, 2025 11:59 PM ET. For shares held in a Plan, vote by June 14, 2025 11:59 PM ET. Visit www.ProxyVote.com

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V70298-P31069 THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Three Class III Directors For Nominees: 01) Allan Jacobson, Ph.D. 02) David P. Southwell 03) Alethia Young 2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. Approval on a non-binding, advisory basis, of the Company’s named executive officer compensation as described in the proxy statement. For NOTE: To transact any other business that may be properly brought before the meeting or any adjournment or postponement of the meeting.

    Get the next $PTCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTCT

    DatePrice TargetRatingAnalyst
    6/17/2025$80.00Buy
    Truist
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    5/7/2025$40.00Sell → Neutral
    Citigroup
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    3/7/2025$55.00Sector Perform
    Scotiabank
    12/13/2024$45.00 → $67.00Equal-Weight → Overweight
    Morgan Stanley
    12/3/2024$39.00 → $63.00Sector Perform → Outperform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    More analyst ratings

    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on PTC Therapeutics with a new price target

    Truist initiated coverage of PTC Therapeutics with a rating of Buy and set a new price target of $80.00

    6/17/25 7:50:47 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00

    5/9/25 8:40:13 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics upgraded by Citigroup with a new price target

    Citigroup upgraded PTC Therapeutics from Sell to Neutral and set a new price target of $40.00

    5/7/25 8:34:42 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Klein Matthew B. was granted 75,000 shares and sold $555,636 worth of shares (10,739 units at $51.74), increasing direct ownership by 23% to 337,767 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    8/5/25 8:30:04 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Gravier Pierre sold $124,441 worth of shares (2,516 units at $49.46), decreasing direct ownership by 3% to 71,920 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    7/17/25 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXEC. VP AND CLO Boulding Mark Elliott exercised 2,812 shares at a strike of $25.69 and sold $129,717 worth of shares (2,812 units at $46.13) (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    5/19/25 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PTCT
    SEC Filings

    View All

    PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    8/19/25 8:10:10 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by PTC Therapeutics Inc.

    10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    8/7/25 4:36:15 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    8/7/25 4:30:13 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

    WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia. "We are of course disappointed by the FDA's decision to not approve vatiquinone," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "We believe the data collected to date demonstrate that vatiquinone could provide a safe and effective therapy for both children and adults living with Friedreich's ataxia. We plan to meet with the FDA to discuss potentia

    8/19/25 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    – European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025.  "We had another strong quarter highlighted by the first approvals of Sephience for the treatment of children and adults with PKU," said Matthew B. Klein, M.D., Chief Executive Officer. "We have initiated the global launch and expect Sephience to be the foundational product for PTC's future growth and path to profitability." Key Corporate Updates:  Sec

    8/7/25 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

    - Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, July 28th at 5:00 pm ET - WARREN, N.J., July 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU. "We are excited to have reached this important milestone for those affected by PKU," said Matthew

    7/28/25 4:19:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    – European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025.  "We had another strong quarter highlighted by the first approvals of Sephience for the treatment of children and adults with PKU," said Matthew B. Klein, M.D., Chief Executive Officer. "We have initiated the global launch and expect Sephience to be the foundational product for PTC's future growth and path to profitability." Key Corporate Updates:  Sec

    8/7/25 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

    - Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, July 28th at 5:00 pm ET - WARREN, N.J., July 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU. "We are excited to have reached this important milestone for those affected by PKU," said Matthew

    7/28/25 4:19:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results

    WARREN, N.J., July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025 financial results and provide an update on the company's business and outlook on Thursday, August 7, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Invest

    7/21/25 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    12/14/23 4:38:32 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Leadership Updates

    Live Leadership Updates

    View All

    Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

    9/12/23 8:00:00 AM ET
    $PTCT
    $SPRO
    $TCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

    SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein

    7/17/23 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/8/24 10:52:39 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    10/18/24 10:57:11 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care